Raven Industries Debuts Driverless Ag Technology on Case IH Magnum™ at U.S. Farm Show
31.8.2021 16:15:00 EEST | Business Wire | Press release
Raven Industries, Inc. (the Company; NASDAQ:RAVN), the leader in Driverless Ag Technology, announced today it will showcase and demonstrate the company’s OMNi suite of technology at Farm Progress Show, one of the largest public farm shows in the United States. At the show, Raven will feature its industry-leading technology in the event’s Autonomy Zone, where the company will debut OMNiDRIVE™ on Case IH Magnum™ and showcase OMNiPOWER™ performing autonomous missions. The public can experience OMNi August 31 through September 2, 2021, from 8:00 a.m. – 5:00 p.m. daily.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210831005184/en/
OMNiDRIVE™ by Raven is the first Driverless Ag Technology for grain cart harvest operations. (Photo: Business Wire)
Raven’s go-to-market strategy for OMNiDRIVE and dealer commitments for the technology are exceeding expectations. OMNiDRIVE was launched by Raven on May 12, 2021, with a year one limited release of 75 aftermarket systems. Today, all systems have been committed to by founding dealers. Through the remainder of the summer, the company is holding OMNiDRIVE demonstration events, where participants get a first-hand view of OMNiDRIVE controlling a driverless tractor pulling a grain cart and commanding it to sync with a harvester. Those interested in experiencing OMNiDRIVE and learning how the technology can dramatically impact their farm operations can sign up on ravenprecision.com/events.
OMNiDRIVE demonstrations this summer are being hosted by the company’s Founders Club members across the United States. Raven created the Founders Club, an elite group of dealers, to enhance the customer experience for ag professionals researching new driverless ag technology through OMNi’s first season of operation. The Founders Club involves intensive dealer training and demonstration requirements that help ag professionals think through a successful Path to Autonomy© for their operation.
“We recognize the challenges our farmers face daily,” said Jim Lilleberg, Director of Precision Ag and Machine Control for Titan Machinery, Inc. “Labor shortages, the need for efficiency improvements and scalability are all problems that OMNiDRIVE, now available for Case IH Magnum tractors, helps solve. We pride ourselves on being at the forefront of cutting-edge technology and the trusted partner to help enable it for our farmers. We feel this is the next major revolution in agriculture, and we are excited to be part of it!”
OMNiDRIVE™ is Raven’s aftermarket technology solution that transforms existing tractors into driverless machines. The technology connects, manages, and safely operates autonomous agricultural machinery and is compatible with:
- Case IH Magnum CVT (2014-2020 models): M250 / 280 / 310 / 340 / 380 (available in October 2021)
- New Holland CVT (2014-2020 models): T8.320 / 350 / 380 / 410 / 435 (available in October 2021)
- John Deere 8Rs Powershift and IVT (2010-current models)
OMNiPOWER™ is a self-propelled power platform that easily interchanges with farm implements, allowing the ag professional to perform multiple farming operations. OMNiPOWER is Raven’s premier platform that visually demonstrates the future of agriculture, drives innovation in the industry, and will accelerate the adoption of advanced autonomous solutions.
To learn more about what to expect from Raven at Farm Progress Show, visit ravenprecision.com/events/farm-progress-show.
About Raven Industries, Inc.
Raven Industries (NASDAQ: RAVN) provides innovative, high-value products and systems that solve great challenges throughout the world. Raven is a leader in precision agriculture, high-performance specialty films, and aerospace and defense solutions, and the company’s groundbreaking work in autonomous systems is unlocking new possibilities in areas like farming, national defense, and scientific research. Since 1956, Raven has designed, produced, and delivered exceptional solutions, earning the company a reputation for innovation, product quality, and unmatched service. For more information, visit https://ravenind.com/.
About Raven Applied Technology
For decades, Raven Applied Technology has been committed to maximizing operational efficiencies through its innovative agriculture technology. The company’s autonomous product suite, Raven Autonomy™, is an extension of that core. From field computers to sprayer and planter controls, GPS guidance steering systems, logistics technology, and autonomous solutions — Raven provides precision agriculture products designed for ag retailers and growers to remain competitive and profitable into the future. Learn more at https://ravenprecision.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210831005184/en/
Contact information
Erin Rinehart, Marketing Manager
Raven Industries
+1 (605) 809-2956
erin.rinehart@ravenind.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Wyss Geneva Steps Into Its Next Chapter11.6.2026 14:33:00 EEST | Press release
The Wyss Center for Bio and Neuroengineering in Geneva is pleased to announce the appointment of Dr. Tracy Laabs as Director, effective July 1st 2026. Dr. Laabs succeeds Prof. Dr. Erwin Böttinger, who leaves behind a fundamentally transformed organization: one that no longer just pursues breakthrough science but systematically turns it into ventures that reach patients. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260611328520/en/ Dr. Tracy Laabs, incoming Director, Wyss Center Geneva Since joining the Wyss Center as Director in April 2023, Prof. Böttinger brought a bold vision: to evolve the Center from a portfolio of promising projects into a disciplined engine for venture creation. Under his leadership, the Center spun off six companies in two years (including ABILITY Neurotech SA and Clee Medical SA in 2025) while simultaneously building a robust pipeline of next-generation programs in AI-guided neuromodulation and min
BeOne Showcases Landmark Phase 3 Data in CLL Patients Aged 80+ at EHA 2026, Reinforcing BRUKINSA Benefit11.6.2026 14:24:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced the presentation of a large Phase 3 dataset in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) aged 80 and older, showing sustained benefit with BRUKINSA after nearly 6.5 years of follow-up, reinforcing its role as the foundational BTK inhibitor. BRUKINSA is the only BTK inhibitor to demonstrate superior efficacy vs. ibrutinib in a Phase 3 trial.1 These data, one of the largest datasets of older patients with treatment-naive CLL, will be presented at the 2026 European Hematology Association (EHA) Congress in Stockholm, Sweden. Amit Agarwal, M.D., Ph.D., Chief Medical Officer, Hematology, BeOne Medicines, said: "While the median age of diagnosis for CLL is 70 and the average age of treatment initiation is 75, many pivotal trials still underrepresent the patients that physicians most often see in practice. These data show that the durable benefit of
Clearlake Expands Liquid Credit Platform With Acquisition of LCM Asset Management’s CLO Contracts11.6.2026 14:00:00 EEST | Press release
Clearlake Capital Group, L.P. (“Clearlake” or the “Firm”), a global investment firm managing integrated platforms spanning private equity, liquid and private credit, and other related strategies, today announced that its credit platform, Clearlake Credit, will assume management of CLOs managed by LCM Asset Management, LLC. The transaction adds 31 CLOs representing more than $5 billion of assets under management and increases assets managed by Clearlake Credit to approximately $39 billion across liquid credit, private credit, and other customized credit solutions. The acquisition further broadens the Firm’s capabilities, deepens its relationships with institutional investors, and reinforces its client-centric approach and commitment to seeking attractive risk-adjusted returns across market cycles. Milbank LLP and Dechert LLP represented Clearlake Credit in the transaction. GreensLedge Capital Markets advised the seller. About Clearlake Clearlake Capital is a leading global alternative a
Takeda’s Zasocitinib Significantly Outperforms Deucravacitinib in Head-to-Head Phase 3 Psoriasis Study, Promising to Redefine Oral Treatment Expectations11.6.2026 14:00:00 EEST | Press release
Takeda (TSE:4502/NYSE:TAK) announced positive topline results for the Phase 3, randomized, multicenter, double-blind study comparing zasocitinib (TAK-279), an investigational, next-generation, highly selective and potent oral tyrosine kinase 2 (TYK2) inhibitor, to deucravacitinib in adults with moderate-to-severe plaque psoriasis (PsO). In the LATITUDE Atlas (TAK-279-PsO-3004) head-to-head study, zasocitinib demonstrated statistical superiority over deucravacitinib for the primary endpoint, Psoriasis Area and Severity Index (PASI) 100 response rate at week 16. The study also demonstrated statistical superiority over deucravacitinib for all key secondary endpoints, including PASI 90 response and Static Physician's Global Assessment (sPGA) 0 at week 16. Zasocitinib was generally well tolerated with a consistent safety and tolerability profile and no new safety signals identified. Perspectives on head-to-head zasocitinib study “In this head-to-head study, zasocitinib clearly demonstrated
L&T Technology Services, Databricks Partner to Deliver Industrial AI at Scale for Asset-Intensive Industries11.6.2026 13:30:00 EEST | Press release
L&T Technology Services (BSE: 540115, NSE: LTTS), a global leader in AI, Digital & ER&D Consulting Services, today announced a strategic go-to-market partnership with Databricks, the leading Data and AI company, to co-develop and deliver Industrial AI solutions that advance Engineering Intelligence (EI) for asset-intensive enterprises. Anchored in LTTS' Sustainability segment, spanning Process Engineering, Discrete Manufacturing and Industrial Products, the partnership will support Energy, Petrochemicals and Industrials clients globally. As industrial organizations seek to unlock greater value from decades of operational and engineering data, the alliance will combine LTTS’ deep domain capabilities with the Databricks platform to transform complex plant data into Engineering Intelligence - enabling improved asset reliability, operational efficiency and sustainability performance. The partnership brings together LTTS’ expertise in forward looking technologies and extensive experience ac
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom